DFFN Stock, Diffusion Pharmaceuticals Inc. Information

Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments including radiation therapy and chemotherapy. Diffusion is developing its lead drug, trans sodium crocetinate TSC , for use in the many cancer types in which tumor hypoxia oxygen deprivation is known to diminish the effectiveness of current treatments. TSC targets the cancer s hypoxic micro environment, re oxygenating treatment resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects. TSC has potential application in other indications involving hypoxia, such as stroke and neurodegenerative diseases. A Phase II clinical program, completed in the second quarter of , evaluated patients with newly diagnosed glioblastoma multiforme GBM . The study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care. This trial has been the basis for discussions with the U.S. Food and Drug Administration. A Phase III program in newly diagnosed GBM is being planned. Additional planned studies include a Phase II/III trial in pancreatic cancer. TSC s novel mechanism safely re oxygenates a range of tumor types, so its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve current standard of care treatments of many life threatening cancers.